MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:40Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Prokinetics]]
			[[Category:Antiemetics]]
			[[Category:Dopamine D2 antagonists]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #256

2026-05-23T04:04:22Z

parser-claude batch MedTemplate pre-fill, Top 300 #256

New page

{{MedTemplate
| generic = Metoclopramide
| brand = Reglan, Gimoti (intranasal), Metozolv ODT
| structure =
| classes = [[:Category:Prokinetics|Prokinetic]], [[:Category:Antiemetics|Antiemetic]], [[:Category:Dopamine_D2_antagonists|Dopamine D2 antagonist]]
| uses = <vote slug="gastroparesis-use">Gastroparesis</vote>, <vote slug="gerd-refractory-use">GERD (refractory; short-term)</vote>, <vote slug="ponv-use">Postoperative nausea and vomiting</vote>, <vote slug="cinv-use">Chemotherapy-induced nausea and vomiting (less first-line since 5-HT3 antagonists)</vote>, <vote slug="migraine-rescue-use">Migraine rescue (with NSAID or triptan)</vote>
| starting_dose = 10 mg PO/IV/IM QID, '''not to exceed 12 weeks''' (tardive dyskinesia risk); intranasal Gimoti 15 mg BID
| preparations = 5, 10 mg tablets; 5 mg/5 mL solution; 5 mg/mL IV; 15 mg/spray intranasal
| fda_max = 40 mg/d
| pill_id =
| routes = Oral, IV, IM, intranasal
| onset = IV/IM 1-3 minutes; PO 30-60 minutes
| duration = 4-6 hours
| halflife = 5-6 hours<ref name="reglan-label">FDA Prescribing Information, Reglan (metoclopramide), ANI, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/017854s064,017862s080lbl.pdf</ref>
| bioavailability = ~80% (oral; reduced by significant first-pass)<ref name="reglan-label" />
| pregnancy = Widely used for hyperemesis gravidarum; reassuring data.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US. Carries a '''Boxed Warning''' for '''tardive dyskinesia''' (irreversible movement disorder), driving the 12-week chronic-use limit<ref name="reglan-label" />
| mechanism = <vote slug="metoclopramide-mech-claim">Metoclopramide antagonizes D2 dopamine receptors in the area postrema (antiemetic effect) and sensitizes gut tissue to acetylcholine, increasing lower esophageal sphincter tone, gastric antral contractions, and small bowel motility (the prokinetic effect); 5-HT4 agonism is a secondary mechanism contributing to prokinesis.</vote> D2 antagonism is also the source of the extrapyramidal adverse effects: acute dystonia (especially in young women), akathisia, parkinsonism, and the boxed-warning tardive dyskinesia (cumulative-dose and chronic-use dependent). Domperidone has the same prokinetic effect with less CNS penetration but is not FDA-approved in the US<ref name="reglan-label" />.
}}

== References ==
<references />

Metoclopramide - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #256